Cabaletta Bio (Nasdaq: CABA) priced an underwritten offering of 51,725,000 shares of common stock at $2.90 per share, generating gross proceeds of approximately $150 million. The company’s current cash balance of $133.6 million, combined with the new capital, is expected to support operations through the end of 2026 and extend the runway into the middle of 2027, according to the company’s financial guidance.
The proceeds will be directed toward advancing the company’s lead CD19‑CAR T therapy, rese‑cel, and expanding manufacturing capacity. Cabaletta recently secured a 10‑year commercial supply agreement with Cellares for automated production of rese‑cel, a move that will help scale the therapy and reduce per‑unit costs. The offering attracted significant institutional investors, including Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, and Eli Lilly, underscoring confidence in the company’s pipeline and strategy.
Investors reacted positively to the pricing announcement, reflecting confidence in the capital raise and the company’s ability to fund its clinical and manufacturing plans. The participation of well‑known institutional investors further signals strong market support for Cabaletta’s growth trajectory.
By extending its cash runway, Cabaletta can continue to progress rese‑cel through Phase 1/2 trials and prepare for potential regulatory submissions, while also mitigating the risk of a liquidity crunch. The equity sale will dilute existing shareholders, but the company’s management has emphasized that the dilution is a necessary trade‑off to secure the resources required for its long‑term development roadmap.
Overall, the equity offering positions Cabaletta Bio to maintain momentum in its autoimmune disease pipeline, strengthen its manufacturing footprint, and sustain operations well beyond the current fiscal horizon, providing a clearer path toward future milestones and potential commercial launch.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.